<DOC>
	<DOCNO>NCT00128843</DOCNO>
	<brief_summary>This pivotal phase II , multicenter , open-label trial , design compare efficacy exemestane versus anastrozole first line treatment advance breast cancer . One hundred postmenopausal patient , metastatic , positive hormone receptor breast cancer enrol trial .</brief_summary>
	<brief_title>Exemestane Versus Anastrozole First Line Hormone Therapy Postmenopausal Metastatic Breast Cancer Patients</brief_title>
	<detailed_description>The primary study endpoint objective response rate . The study design follow Simon 's test , p1-p0=0.15 . p1 optimum level activity experimental treatment ( exemestane ) , p0 minimum expect activity . In study , p1 25 % ( 25 % RR ) p0 10 % ( 10 % RR ) . With alpha error 0.05 beta error 0.1 , Simon test establishes first step 21 patient per treatment arm . If least 2 objective response observe exemestane arm , recruitment continue 100 patient recruit . After second recruitment phase , least 7 objective response must observe confirm expect exemestane level activity .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<criteria>Pathological diagnosis breast cancer . Postmenopausal woman , define : Bilateral surgical oophorectomy amenorrhoea &gt; = 5 year ; Age &gt; = 56 year old amenorrhoea &gt; = 1 year ; Chemotherapy induce amenorrhoea &gt; = 2 year ; Radiotherapy induce amenorrhoea least 3 month : Age &lt; 56 &lt; 5 year amenorrhoea : folliclestimulating hormone ( FSH ) level confirm postmenopausal status . Metastatic breast cancer ( stage IV ) nonoperable locally advanced breast cancer ( stage IIIB ) . Positive estrogen and/or progesterone receptor &gt; 10 % cell &gt; 10fmol/mg . Measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) criterion . Patients receive adjuvant tamoxifen eligible , progression establish least 24 month since treatment start . Neoadjuvant chemotherapy allow progression establish least 12 month end treatment . Patients may receive first line chemotherapy advance disease , treatment must end least 4 week enrolment , acute toxicity must resolve . Previous treatment Herceptin allow . Normal haematological , hepatic renal function . Performance status ECOG 0 , 1 , 2 . Life expectancy superior 3 month . Written informed consent . Previous hormone treatment metastatic disease . Previous treatment aromatase inhibitor . Inflammatory breast cancer , aggressive metastatic disease , visceral lesion , metastasis central nervous system ( CNS ) . Nonmeasurable disease . Second malignancy except basal skin carcinoma cervical situ carcinoma adequately treat . If malignancy , patient must diseasefree period superior 5 year . Treatment investigational product 4 previous week . Patients negative estrogen progesterone receptor tumour .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>First line hormone treatment</keyword>
	<keyword>Postmenopausal woman</keyword>
	<keyword>Positive hormone receptor tumour</keyword>
</DOC>